| pubmed-article:2506702 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2506702 | lifeskim:mentions | umls-concept:C0008972 | lld:lifeskim |
| pubmed-article:2506702 | lifeskim:mentions | umls-concept:C0017628 | lld:lifeskim |
| pubmed-article:2506702 | lifeskim:mentions | umls-concept:C1704410 | lld:lifeskim |
| pubmed-article:2506702 | lifeskim:mentions | umls-concept:C0524527 | lld:lifeskim |
| pubmed-article:2506702 | lifeskim:mentions | umls-concept:C0521116 | lld:lifeskim |
| pubmed-article:2506702 | lifeskim:mentions | umls-concept:C1280519 | lld:lifeskim |
| pubmed-article:2506702 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:2506702 | pubmed:dateCreated | 1989-10-20 | lld:pubmed |
| pubmed-article:2506702 | pubmed:abstractText | In a clinical study efficacy and tolerance of Neogluconin (2.5 mg) a new galenical form of glibenclamide were compared with a conventional preparation (Euglucon 5). Neogluconin showed an improved absorption and comparable blood sugar levels at a dosage reduced by 25%. 25 outpatients suffering from Type II diabetes in a well balanced metabolic state and previously under Euglucon therapy for at least one year were changed to the new product. After 2 months of Neogluconin therapy blood sugar profiles, HbA1, C-peptide and cholesterin levels were unchanged in comparison to values determined during the previous Euglucon treatment. This confirms that Neogluconin produces a comparable favorable blood glucose lowering effect despite a 25% reduction in dosage. | lld:pubmed |
| pubmed-article:2506702 | pubmed:language | ger | lld:pubmed |
| pubmed-article:2506702 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2506702 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2506702 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2506702 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2506702 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2506702 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2506702 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2506702 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:2506702 | pubmed:issn | 0043-5341 | lld:pubmed |
| pubmed-article:2506702 | pubmed:author | pubmed-author:LinggGG | lld:pubmed |
| pubmed-article:2506702 | pubmed:author | pubmed-author:HaushoferAA | lld:pubmed |
| pubmed-article:2506702 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2506702 | pubmed:day | 30 | lld:pubmed |
| pubmed-article:2506702 | pubmed:volume | 139 | lld:pubmed |
| pubmed-article:2506702 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2506702 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2506702 | pubmed:pagination | 281-4 | lld:pubmed |
| pubmed-article:2506702 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2506702 | pubmed:meshHeading | pubmed-meshheading:2506702-... | lld:pubmed |
| pubmed-article:2506702 | pubmed:meshHeading | pubmed-meshheading:2506702-... | lld:pubmed |
| pubmed-article:2506702 | pubmed:meshHeading | pubmed-meshheading:2506702-... | lld:pubmed |
| pubmed-article:2506702 | pubmed:meshHeading | pubmed-meshheading:2506702-... | lld:pubmed |
| pubmed-article:2506702 | pubmed:meshHeading | pubmed-meshheading:2506702-... | lld:pubmed |
| pubmed-article:2506702 | pubmed:meshHeading | pubmed-meshheading:2506702-... | lld:pubmed |
| pubmed-article:2506702 | pubmed:meshHeading | pubmed-meshheading:2506702-... | lld:pubmed |
| pubmed-article:2506702 | pubmed:meshHeading | pubmed-meshheading:2506702-... | lld:pubmed |
| pubmed-article:2506702 | pubmed:meshHeading | pubmed-meshheading:2506702-... | lld:pubmed |
| pubmed-article:2506702 | pubmed:meshHeading | pubmed-meshheading:2506702-... | lld:pubmed |
| pubmed-article:2506702 | pubmed:meshHeading | pubmed-meshheading:2506702-... | lld:pubmed |
| pubmed-article:2506702 | pubmed:meshHeading | pubmed-meshheading:2506702-... | lld:pubmed |
| pubmed-article:2506702 | pubmed:meshHeading | pubmed-meshheading:2506702-... | lld:pubmed |
| pubmed-article:2506702 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2506702 | pubmed:articleTitle | [Clinical study comparing the effectiveness and tolerance of 2 current and one new glibenclamide formulation]. | lld:pubmed |
| pubmed-article:2506702 | pubmed:affiliation | Interne Abteilung, a. ö. Krankenhaus, Dornbirn. | lld:pubmed |
| pubmed-article:2506702 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2506702 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2506702 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2506702 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:2506702 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
